KR102335082B1 - 헤테로사이클릭 화합물 및 이의 용도 - Google Patents

헤테로사이클릭 화합물 및 이의 용도 Download PDF

Info

Publication number
KR102335082B1
KR102335082B1 KR1020197019661A KR20197019661A KR102335082B1 KR 102335082 B1 KR102335082 B1 KR 102335082B1 KR 1020197019661 A KR1020197019661 A KR 1020197019661A KR 20197019661 A KR20197019661 A KR 20197019661A KR 102335082 B1 KR102335082 B1 KR 102335082B1
Authority
KR
South Korea
Prior art keywords
compound
alkyl
heteroaryl
heterocycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197019661A
Other languages
English (en)
Korean (ko)
Other versions
KR20190104334A (ko
Inventor
추안 시
각-산 시아
치엔-황 우
밍-첸 최
젠-신 송
윤 왕
Original Assignee
내셔날 헬스 리서치 인스티튜트
추안 시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 내셔날 헬스 리서치 인스티튜트, 추안 시 filed Critical 내셔날 헬스 리서치 인스티튜트
Publication of KR20190104334A publication Critical patent/KR20190104334A/ko
Application granted granted Critical
Publication of KR102335082B1 publication Critical patent/KR102335082B1/ko
Assigned to 내셔날 헬스 리서치 인스티튜트 reassignment 내셔날 헬스 리서치 인스티튜트 권리지분의 전부이전등록 Assignors: 시 추안
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197019661A 2017-01-10 2018-01-08 헤테로사이클릭 화합물 및 이의 용도 Active KR102335082B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444601P 2017-01-10 2017-01-10
US62/444,601 2017-01-10
PCT/US2018/012748 WO2018132326A1 (en) 2017-01-10 2018-01-08 Heterocyclic compounds and use thereof

Publications (2)

Publication Number Publication Date
KR20190104334A KR20190104334A (ko) 2019-09-09
KR102335082B1 true KR102335082B1 (ko) 2021-12-06

Family

ID=62839630

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197019661A Active KR102335082B1 (ko) 2017-01-10 2018-01-08 헤테로사이클릭 화합물 및 이의 용도

Country Status (10)

Country Link
US (1) US10882854B2 (https=)
EP (1) EP3568137A4 (https=)
JP (1) JP6982716B2 (https=)
KR (1) KR102335082B1 (https=)
CN (1) CN110381949B (https=)
AU (1) AU2018208366B2 (https=)
CA (1) CA3047146C (https=)
RU (1) RU2756055C2 (https=)
TW (1) TWI664174B (https=)
WO (1) WO2018132326A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110176278B (zh) * 2019-05-24 2021-09-28 河海大学 氨基酸氯化生成二氯乙腈的连续反应动力学模型建模方法
WO2023014611A1 (en) * 2021-08-02 2023-02-09 Yeh, Teng-Kuang Pyrimidine compounds and use thereof
TW202345843A (zh) * 2022-04-06 2023-12-01 財團法人國家衛生研究院 脂質奈米顆粒及脂質體

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160083369A1 (en) * 2014-09-22 2016-03-24 National Health Research Institutes Heterocyclic compounds and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW550258B (en) * 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
WO2004052862A1 (ja) * 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
JP5118029B2 (ja) 2005-06-14 2013-01-16 タイゲン バイオテクノロジー カンパニー，リミテッド ピリミジン化合物
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
JP2009541480A (ja) 2006-06-30 2009-11-26 アストラゼネカ アクチボラグ 癌の治療において有用なピリミジン誘導体
EP2043651A2 (en) * 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
AU2008355098B2 (en) * 2008-04-21 2012-11-15 Gpcr Therapeutics, Inc Heterocyclic compounds
TWI409265B (zh) 2008-08-20 2013-09-21 Merck Sharp & Dohme 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160083369A1 (en) * 2014-09-22 2016-03-24 National Health Research Institutes Heterocyclic compounds and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry, 2015, 제58권, 페이지 2315-2325

Also Published As

Publication number Publication date
WO2018132326A1 (en) 2018-07-19
RU2019124448A3 (https=) 2021-02-26
JP6982716B2 (ja) 2021-12-17
TW201831466A (zh) 2018-09-01
AU2018208366B2 (en) 2020-12-17
JP2020506879A (ja) 2020-03-05
CA3047146A1 (en) 2018-07-19
CA3047146C (en) 2021-08-31
CN110381949B (zh) 2023-12-08
US20180208588A1 (en) 2018-07-26
BR112019013493A2 (pt) 2020-01-07
US10882854B2 (en) 2021-01-05
EP3568137A4 (en) 2020-05-27
KR20190104334A (ko) 2019-09-09
RU2019124448A (ru) 2021-02-12
AU2018208366A1 (en) 2019-06-27
RU2756055C2 (ru) 2021-09-24
EP3568137A1 (en) 2019-11-20
TWI664174B (zh) 2019-07-01
NZ754272A (en) 2021-05-28
CN110381949A (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
US20230118629A1 (en) Substituted piperazine derivatives useful as t cell activators
JP6615207B2 (ja) 複素環式化合物及びその使用
KR102335082B1 (ko) 헤테로사이클릭 화합물 및 이의 용도
JPH06503344A (ja) 可溶性の補体受容体と、補体を抑制しかつ／または免疫活性を抑制する化合物との相乗組成物
AU2024281056A1 (en) Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024254227A1 (en) Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
HK40010586A (en) Heterocyclic compounds and use thereof
CN116323607A (zh) 用作alk5抑制剂的萘啶衍生物
HK40010586B (zh) 杂环化合物及其用途
EP3200796B1 (en) 4-aminopyrimidine compounds in combination with a chemotherapy agent for treating cancer
NZ754272B2 (en) Heterocyclic compounds and use thereof
BR112019013493B1 (pt) Compostos heterocíclicos e seus usos, composição farmacêutica e método de mobilização de células-tronco hematopoiéticas e células progenitoras endoteliais na circulação periférica
HK1240496A1 (en) 4-aminopyrimidine compounds in combination with a chemotherapy agent for treating cancer
HK1240496B (en) 4-aminopyrimidine compounds in combination with a chemotherapy agent for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190705

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201211

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20201211

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210325

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210726

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20211015

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211130

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211201

End annual number: 3

Start annual number: 1

PG1601 Publication of registration